Beatrice Bernhart
Medical · Saint Louis, MONPI 1740452564
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 861 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 861 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$2K
- Amgen$2K
- Pfizer$1K
- Novartis$1K
- AstraZeneca$1K
- plus $5K from 30 others
What the payments were for
- Food & beverage$14,65698%
- Education$3332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 158 | $2,754 |
| Johnson & Johnson | 106 | $2,047 |
| Amgen(2 entities) | 133 | $1,861 |
| Pfizer | 91 | $1,259 |
| Novartis | 83 | $1,259 |
| AstraZeneca(2 entities) | 49 | $1,038 |
| UCB, Inc. | 50 | $972 |
| Lilly USA, LLC | 38 | $662 |
| GSK | 41 | $631 |
| E.r. Squibb & Sons, L.L.C. | 18 | $315 |
| Radius Health, Inc. | 13 | $266 |
| Teva Pharmaceuticals USA, Inc. | 6 | $228 |
| Sobi, Inc | 9 | $226 |
| Organon | 8 | $198 |
| Aurinia Pharma U.S., Inc. | 10 | $193 |
| Boehringer Ingelheim | 8 | $161 |
| Janssen Scientific Affairs, LLC | 1 | $119 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| ANI Pharmaceuticals, Inc. | 4 | $84 |
| Sandoz | 5 | $79 |
| Mallinckrodt Hospital Products Inc. | 3 | $70 |
| Octapharma USA, Inc. | 3 | $66 |
| Pacira Therapeutics, Inc. | 4 | $55 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $49 |
| Grifols USA, LLC | 2 | $40 |
| Genentech USA, Inc. | 3 | $39 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $38 |
| Hospira, Inc. | 1 | $34 |
| Kyowa Kirin, Inc. | 2 | $33 |
| Tersera Therapeutics LLC | 1 | $28 |
| Sanofi | 1 | $22 |
| Celltrion USA Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Invivyd Inc | 1 | $14 |
| Fresenius Kabi USA, LLC | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,989 in reported general payments places this provider in the 90th percentile of 198 medical providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 16 | $226,614 |
| Enbrel SureclickEtanercept | 24 | $194,767 |
| Cosentyx Unoready PenSecukinumab | 15 | $109,436 |
| Orencia ClickjectAbatacept | 14 | $89,414 |
| RinvoqUpadacitinib | 13 | $85,522 |
| Leflunomide | 176 | $9,924 |
| Hydroxychloroquine Sulfate | 172 | $7,563 |
| Mycophenolate Mofetil | 55 | $7,498 |
| Azathioprine | 109 | $5,754 |
| MethotrexateMethotrexate Sodium | 174 | $3,621 |
| Prednisone | 255 | $1,788 |
| Duloxetine Hcl | 67 | $1,448 |
| Gabapentin | 75 | $1,038 |
| Sulfasalazine DrSulfasalazine | 13 | $564 |
| Triamcinolone Acetonide | 17 | $527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $2,047 | $226,61416 claims |
| AbbVieRinvoq | $2,754 | $85,52213 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $14 | $6019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 198 medical providers in Missouri.
Other medical in Saint Louis
- Amy MosmanSaint Louis$21K
- Alexa Fider-WhyteSaint Louis$18K
- Megan Isaacson-SchmidSaint Louis$16K
- Erin YoffieSaint Louis$16K
- Lindsay ExlineSaint Louis$8K
- Mustafa AhmedSaint Louis$8K
- Elizabeth HowardSaint Louis$4K
- Macara JacobsSaint Louis$4K
- Kayla BergmannSaint Louis$4K
- David VanhoornbeekSaint Louis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.